FMP

FMP

Enter

MLND - Millendo Therap...

photo-url-https://images.financialmodelingprep.com/symbol/MLND.png

Millendo Therapeutics, Inc.

MLND

NASDAQ

Inactive Equity

Millendo Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing novel treatments for orphan endocrine diseases in the United States. Its lead product candidates include livoletide, a potential treatment for Prader-Willi syndrome; nevanimibe, a potential treatment for patients with classic congenital adrenal hyperplasia; and MLE-301, a neurokinin 3-receptor antagonist for the treatment of vasomotor symptoms in menopausal women. The company is headquartered in Ann Arbor, Michigan.

1.06 USD

-0.06000006 (-5.66%)

Historical Prices

From:

To:

page loading card

About

ceo

Dr. Julia Owens

sector

Healthcare

industry

Biotechnology

exchange

NASDAQ

Description

Millendo Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing novel treatments for orphan endocrine diseases in the United States. Its lead product candidates include livoletide, a potential treatment for Prader-Willi syndrome; nevanimibe, a potential treatment for patients with classic congenital adrenal hyperplasia; and MLE-301, a neurokinin 3-receptor antagonist for the treatment of vasomotor symptoms in menopausal women. The company is headquartered in Ann Arbor, Michigan.

CIK

0001544227

ISIN

US60040X1037

CUSIP

60040X103

Address

110 Miller Ave Ste 100

Phone

17348459000

Country

US

Employee

12

IPO Date

Oct 4, 2012

Financial Statement

Earnings

We are unable to load the chart at this time.

fmp-logo

MLND Financial Summary

CIK

0001544227

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

60040X103

ISIN

US60040X1037

Country

US

Price

1.06

Beta

0.48

Volume Avg.

140.97k

Market Cap

11.15M

Shares

-

52-Week

1.06-1.13

DCF

31.42

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

0

P/B

-

Website

http://www.millendo.com

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

Latest MLND News

GlobeNewsWire

Jun 22, 2021

Tempest and Millendo Announce Stockholder Approval of Merger

Tempest to Trade on Nasdaq Public Markets Under Ticker “TPST” Tempest to Trade on Nasdaq Public Markets Under Ticker “TPST”

Business Wire

Apr 7, 2021

MILLENDO INVESTOR ALERT by The Former Attorney General of Lo...

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Millendo Therapeutics, Inc. (NasdaqGS: MLND) (“the Company”) with Tempest Therapeutics, Inc. pursuant to which Millendo shareholders are expected to only own approximately 18.5% of the combined company, subject to adjustments. KSF is seeking to determine whether the merger and the process that led to it are

PRNewsWire

Apr 2, 2021

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an I...

NEW YORK, April 2, 2021 /PRNewswire/ --  Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Millendo Therapeutics, Inc. ("MLND" or the "Company") ( MLND ) relating to its proposed merger with Tempest Therapeutics, Inc. Under the terms of the agreement, MLND shareholders are expected to...

Business Wire

Mar 31, 2021

Millendo Merger Investigation: Halper Sadeh LLP Announces In...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger of Millendo Therapeutics, Inc. (NASDAQ: MLND) and Tempest Therapeutics, Inc. is fair to Millendo shareholders. Upon completion of the merger, Millendo shareholders are expected to own approximately 18.5% of the combined company while pre-merger Tempest stockholders will own approximately 81.5% of the combined company. Halper Sadeh encourages Millendo shareholders to click here to

Pulse2

Mar 29, 2021

MLND Stock Price Falls Over 10% Pre-Market: Why It Happened

The stock price of Millendo Therapeutics Inc (NASDAQ: MLND) fell by over 10% pre-market. This is why it happened.

Benzinga

Mar 29, 2021

Tempest Therapeutics To Go Public Via Millendo Therapeutics ...

Millendo Therapeutics Inc (NASDAQ: MLND) has agreed to merge with privately-held Tempest Therapeutics Inc in an all-stock transaction. The combined company will operate under the Tempest Therapeutics moniker under ticker 'TPST,' focusing on advancing Tempest's oncology pipeline of small molecule candidates.

seekingalpha.com

Aug 13, 2020

Millendo Therapeutics (MLND) Investor Presentation - Slidesh...

Yahoo

Aug 10, 2020

Millendo Therapeutics Reports Second Quarter 2020 Operating ...

Millendo Therapeutics Reports Second Quarter 2020 Operating and Financial Results

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep